KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Common Equity (2016 - 2025)

Vertex Pharmaceuticals has reported Common Equity over the past 17 years, most recently at $18.7 billion for Q4 2025.

  • Quarterly results put Common Equity at $18.7 billion for Q4 2025, up 13.75% from a year ago — trailing twelve months through Dec 2025 was $18.7 billion (up 13.75% YoY), and the annual figure for FY2025 was $18.7 billion, up 13.75%.
  • Common Equity for Q4 2025 was $18.7 billion at Vertex Pharmaceuticals, up from $17.3 billion in the prior quarter.
  • Over the last five years, Common Equity for VRTX hit a ceiling of $18.7 billion in Q4 2025 and a floor of $9.0 billion in Q1 2021.
  • Median Common Equity over the past 5 years was $15.1 billion (2023), compared with a mean of $14.3 billion.
  • Biggest five-year swings in Common Equity: skyrocketed 38.98% in 2021 and later fell 11.05% in 2025.
  • Vertex Pharmaceuticals' Common Equity stood at $10.1 billion in 2021, then soared by 37.75% to $13.9 billion in 2022, then rose by 26.36% to $17.6 billion in 2023, then fell by 6.66% to $16.4 billion in 2024, then rose by 13.75% to $18.7 billion in 2025.
  • The last three reported values for Common Equity were $18.7 billion (Q4 2025), $17.3 billion (Q3 2025), and $17.2 billion (Q2 2025) per Business Quant data.